Trial Profile
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Nov 2023
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Chondrosarcoma
- Focus Registrational; Therapeutic Use
- Acronyms CHONQUER
- Sponsors Servier
- 16 Nov 2023 New trial record